ReviewDiabetes2015
Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity.
Review in Diabetes, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 249 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
249 citing papers in PubMed, 403 citations in OpenAlex.
- Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study.Cell reports. Medicine · 2025Trial
- Trial
- Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study.The Journal of clinical endocrinology and metabolism · 2022Trial
- Novel insights of elevated systemic levels of bisphenol-A (BPA) linked to poor glycemic control, accelerated cellular senescence and insulin resistance in patients with type 2 diabetes.Molecular and cellular biochemistry · 2019Trial
- Adipose tissue as a humoral-neuronal hub in metabolic regulation.Nature reviews. Endocrinology · 2026Review
- Senotypes define the diverse landscape of senescent cells.Nature aging · 2026Review
- Review
- Cellular senescence and inflammageing: from mechanisms to senotherapeutic interventions.Biogerontology · 2026Review
- Host-Pathogen Interaction as a Driver of Cellular Senescence: Microbial Triggers and Host Response.International journal of molecular sciences · 2026Review
- Neighborhood opportunity and cellular senescence in a national sample of U.S. adults.Social science & medicine (1982) · 2026Article
- Psychosis as a multisystem disorder of aberrant aging.npj aging · 2026Review
- Alleviation of diabetic cardiomyopathy via preventing VCAM1-positive cells from senescence by engineered nanovesicles.Journal of nanobiotechnology · 2026Article
- Targeting Senescence in Adipose Microvasculature: A New Target Diabetes and Heart Failure.JACC. Basic to translational science · 2026Article
- Dietary Polyphenols in Aging: A Systems-Level Perspective on Mitochondrial Quality Control and Microbiome Interactions.International journal of molecular sciences · 2026Review
- The Association of Ramadan Fasting on Relative Leukocyte Telomere Length in Type 2 Diabetes Mellitus.Journal of the ASEAN Federation of Endocrine Societies · 2026Article
- Peroxisome Proliferator-Activated Receptor α Deficiency Induces Vascular Pathologies through Endothelial Senescence in Diabetic Retinopathy.The American journal of pathology · 2026Article
- Photobiomodulation therapy reduces diabetic periodontal damage through modulation of macrophage metabolism and functions.Lasers in medical science · 2026Article
- Hand pathology in type 1 diabetes mellitus: a case-control study.Hormones (Athens, Greece) · 2026Article
- Proteomics-derived organ-specific aging clusters predict macrovascular and microvascular complications in diabetes.Cardiovascular diabetology · 2026Article
- Translating cellular senescence research into clinical practice for metabolic disease.Nature reviews. Endocrinology · 2026Review
189 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cellular senescence is a fundamental aging mechanism that has been implicated in many age-related diseases and is a significant cause of tissue dysfunction. Accumulation of senescent cells occurs during aging and is also seen in the context of obesity and diabetes. Senescent cells may play a role in type 2 diabetes pathogenesis through direct impact on pancreatic β-cell function, senescence-associated secretory phenotype (SASP)-mediated tissue damage, and involvement in adipose tissue dysfunction. In turn, metabolic and signaling changes seen in diabetes, such as high circulating glucose, altered lipid metabolism, and growth hormone axis perturbations, can promote senescent cell formation. Thus, senescent cells might be part of a pathogenic loop in diabetes, as both a cause and consequence of metabolic changes and tissue damage. Therapeutic targeting of a basic aging mechanism such as cellular senescence may have a large impact on disease pathogenesis and could be more effective in preventing the progression of diabetes complications than currently available therapies that have limited impact on already existing tissue damage. Therefore, senescent cells and the SASP represent significant opportunities for advancement in the prevention and treatment of type 2 diabetes and its complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.